Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash

0 42

Biocon Biologics, on Sunday, announced that it has entered into a definitive agreement with its partner Viatris. As per the agreement, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. 

Viatris will receive up to USD 3.335 billion in the settlement, including up to USD 2.335 billion in cash and USD 1 billion in Compulsorily Convertible Preference Shares (CCPS) in BBL. The transaction has been approved by the boards of directors of both firms.

As a result of this development, BBL will have a comprehensive portfolio comprising its current range of commercialized insulins, oncology, and immunology biosimilars as well as several other biosimilar assets currently under development. The pharma firm also has access to the vaccines portfolio through its previously announced partnership with Serum Institute Life Sciences (SILS).

“This  acquisition is transformational and will create a unique fully integrated, world leading biosimilars enterprise. Our long-standing global partnership with Viatris has enabled us to achieve many firsts, setting new benchmarks for the global biosimilars industry. This strategic combination brings together the complementary capabilities and strengths of both partners and prepares us for the next decade of value creation for all our stakeholders.”

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics

“The deal will enable BBL to attain a robust commercial engine in the developed markets of U.S. & Europe and will fast-track our journey of building a strong global brand. It will also make us future-ready for the next wave of products. This development takes our partnership with Viatris to the next level to realize our shared purpose of impacting global health by providing affordable access to high quality essential and life-saving Biosimilar drugs,” she added.

“By combining the biosimilars business of Viatris to create a global, vertically integrated business in BBL, we are confident of unlocking significant value for our stakeholders. This deal gives BBL full ownership of Viatris’ rights in biosimilars assets, enabling us to recognize combined revenues and profits. To ensure a seamless transition and continued service to patients and customers, Viatris will provide commercial and other transition services to BBL for an expected period of two years.” 

Dr Arun Chandavarkar, Managing Director, Biocon Biologics

“This deal provides several advantages, including strategic agility and operational efficiencies, which will help us mitigate pricing pressures in a competitive global biosimilars landscape. We remain committed to sustainable growth with a strong financial profile, expanded geographical reach and continued investments in R&D to build a world-leading biosimilars franchise. We believe that as a fully integrated global company, we will be able to enhance patient access and reduce healthcare inequities worldwide,” he added.

Once the deal is closed, BBL will step-up from its existing arrangement with Viatris and get the full revenue and associated profits from its partnered products. The deal will expand BBL’s EBITDA base and strengthen overall financials, enabling investments for sustained long-term growth.

“Our unique collaboration with Biocon began more than a decade ago, even before a biosimilars pathway was defined in most countries. During that time, we have experienced many successes, and today is no exception as we join together to create a new, uniquely positioned world class vertically integrated biosimilars leader. This transaction will allow Viatris to continue to participate in the global biosimilars space in a more optimized way, while also allowing us to accelerate our own financial priorities.”

Robert J. Coury, Viatris’ Executive Chairman

Viatris will receive cash consideration of 2 billion US Dollars on the closing of the transaction. And up to 335 million US Dollars as additional payments are expected to be paid in 2024. Additionally, BBL will also issue 1 billion US Dollars of Compulsorily Convertible Preference Shares (CCPS) to Viatris, equivalent to an equity stake of at least 12.9% in the Company, on a fully diluted basis, upon closing of the transaction. Viatris will provide commercial and other transition services for an expected period of two years to ensure continuity of customer service and smooth transition to BBL.

See the Tweet:

Leave A Reply

Your email address will not be published.